Compare FCF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCF | IMNM |
|---|---|---|
| Founded | 1934 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 1994 | 2020 |
| Metric | FCF | IMNM |
|---|---|---|
| Price | $20.29 | $16.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $24.07 | ★ $35.19 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | 5.76 | ★ 51.40 |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $6.49 | N/A |
| Revenue Next Year | $5.68 | $18,803.97 |
| P/E Ratio | $24.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.00 | $14.64 |
| 52 Week High | $22.34 | $30.06 |
| Indicator | FCF | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 21.44 |
| Support Level | $19.85 | N/A |
| Resistance Level | $20.87 | $23.48 |
| Average True Range (ATR) | 0.33 | 0.94 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 67.38 | 2.40 |
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.